Corbus Pharmaceuticals Holdings (STU:3371) FFO


STU:3371 Corbus Pharmaceuticals Holdings Inc STU:3371
37 GF Score
Price €7.57
! 1 Warning Sign
View Full Analysis

What is Corbus Pharmaceuticals Holdings FFO?

FFO (Funds from operations) only applies to REITs.

STU:3371
37GF Score
Corbus Pharmaceuticals Holdings Inc STU:3371
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corbus Pharmaceuticals Holdings Business Description

Other Exchanges CRBP:USA0SZI:UK
Address 500 River Ridge Drive, Norwood, MA, USA, 02062
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
37GF Score

Get the complete analysis for STU:3371

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.57
Price